DoW Autism Clinical Trial Award
Defense Health Agency Contracting Activity - DHACA · Military Medical Research and Development (12.420)
Posted 21 May 2026 · 21 days left
In plain terms
The US Defense Health Agency funds clinical trials on autism treatment and management through its FY26 Autism Research Program, with a total budget of 3.25 million US dollars. Unrestricted applicant types may apply, including early-career investigator partnerships, with a deadline of 22 October 2026.
A generated summary of the donor's text; the original wording is below.
Summary
Summary: The fiscal year 2026 (FY26) Autism Research Program (ARP) Clinical Trial Award supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of autism. Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first-in-human, phase 0) to demonstrate the feasibility or inform the design of more advanced trials through large-scale trials to determine efficacy in relevant patient populations.
Distinctive Features:
Applications are strongly encouraged to address one of the FY26 ARP Clinical Trial Award Areas of Interest.
Partnering Principal Investigator (PI) Option for Early-Career Investigator: The FY26 Clinical Trial Award mechanism is offering a higher level of funding for applications that propose to partner an experienced PI (i.e., Initiating PI) with an Early-Career Investigator (i.e., Partnering PI) wishing to pursue a career in autism clinical trial research.
FY26 Clinical Trial Award submissions are…
Excerpt from the donor's page. The full text, annexes and forms are on the original call.
Who can apply
- ngo_cso
- academia_research
- private_company
- government
- individual
Eligibility and conditions
Show the eligibility text from the source
Applicant types: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"